Plasma Proprotein Convertase Subtilisin/Kexin Type 9 as a Predictor of Carotid Atherosclerosis in Asymptomatic Adults

    Research output: Contribution to journalArticle

    24 Citations (Scopus)
    183 Downloads (Pure)

    Abstract

    Background Atherosclerosis is a lipid-driven inflammatory disease of the arterial wall involving complex and multifactorial processes. Proprotein convertase subtilisin kexin type 9 (PCSK9) may play a role in the development of atherosclerosis. Methods We investigated the associations between serum PCSK9 and carotid intima-medial wall thickness (IMT), a measure of subclinical atherosclerosis that predicts cardiovascular events, in 295 asymptomatic subjects from community. Carotid IMT was determined by high-resolution B-mode carotid ultrasonography and serum PCSK9 was measured by immunoassay. Results In univariate analysis, serum PCSK9 concentration was positively (P<0.05 in all) associated with age (r=0.204), BMI (r=0.149), waist circumference (r=0.139), systolic blood pressures (r=0.116), glucose (r=0.211), insulin (r=0.178), HOMA score (r=0.195), plasma triglyceride (r=0.285), total cholesterol (r=0.241) and LDL-cholesterol concentrations (r=0.172). In multivariate regression including male gender, hypertension, smoking status, HOMA score, obesity, LDL-cholesterol, lipoprotein (a) or markers of inflammation, serum PCSK9 remained an independent predictor of mean carotid IMT (P<0.001). Conclusions These data suggest that serum levels of PCSK9 may contribute to increased risk of subclinical carotid atherosclerosis independent of conventional risk factors. Whether PCSK9 inhibition improves cardiovascular outcomes remains to be demonstrated in large, ongoing clinical trials.
    Original languageEnglish
    Pages (from-to)520-525
    JournalHeart, Lung and Circulation
    Volume25
    Issue number5
    Early online date18 Nov 2015
    DOIs
    Publication statusPublished - May 2016

    Fingerprint

    Carotid Artery Diseases
    Serum
    LDL Cholesterol
    Atherosclerosis
    Blood Pressure
    Lipoprotein(a)
    Waist Circumference
    Proprotein Convertase 9
    Immunoassay
    Ultrasonography
    Triglycerides
    Obesity
    Biomarkers
    Smoking
    Cholesterol
    Clinical Trials
    Insulin
    Hypertension
    Inflammation
    Lipids

    Cite this

    @article{776fd73cea5a4a48bc0e44fc765daa19,
    title = "Plasma Proprotein Convertase Subtilisin/Kexin Type 9 as a Predictor of Carotid Atherosclerosis in Asymptomatic Adults",
    abstract = "Background Atherosclerosis is a lipid-driven inflammatory disease of the arterial wall involving complex and multifactorial processes. Proprotein convertase subtilisin kexin type 9 (PCSK9) may play a role in the development of atherosclerosis. Methods We investigated the associations between serum PCSK9 and carotid intima-medial wall thickness (IMT), a measure of subclinical atherosclerosis that predicts cardiovascular events, in 295 asymptomatic subjects from community. Carotid IMT was determined by high-resolution B-mode carotid ultrasonography and serum PCSK9 was measured by immunoassay. Results In univariate analysis, serum PCSK9 concentration was positively (P<0.05 in all) associated with age (r=0.204), BMI (r=0.149), waist circumference (r=0.139), systolic blood pressures (r=0.116), glucose (r=0.211), insulin (r=0.178), HOMA score (r=0.195), plasma triglyceride (r=0.285), total cholesterol (r=0.241) and LDL-cholesterol concentrations (r=0.172). In multivariate regression including male gender, hypertension, smoking status, HOMA score, obesity, LDL-cholesterol, lipoprotein (a) or markers of inflammation, serum PCSK9 remained an independent predictor of mean carotid IMT (P<0.001). Conclusions These data suggest that serum levels of PCSK9 may contribute to increased risk of subclinical carotid atherosclerosis independent of conventional risk factors. Whether PCSK9 inhibition improves cardiovascular outcomes remains to be demonstrated in large, ongoing clinical trials.",
    author = "Dick Chan and Jing Pang and Brendan Mcquillan and Joe Hung and John Beilby and Hugh Barrett and Gerald Watts",
    year = "2016",
    month = "5",
    doi = "10.1016/j.hlc.2015.10.017",
    language = "English",
    volume = "25",
    pages = "520--525",
    journal = "Heart, Lung & Circulation",
    issn = "1444-2892",
    publisher = "Academic Press",
    number = "5",

    }

    TY - JOUR

    T1 - Plasma Proprotein Convertase Subtilisin/Kexin Type 9 as a Predictor of Carotid Atherosclerosis in Asymptomatic Adults

    AU - Chan, Dick

    AU - Pang, Jing

    AU - Mcquillan, Brendan

    AU - Hung, Joe

    AU - Beilby, John

    AU - Barrett, Hugh

    AU - Watts, Gerald

    PY - 2016/5

    Y1 - 2016/5

    N2 - Background Atherosclerosis is a lipid-driven inflammatory disease of the arterial wall involving complex and multifactorial processes. Proprotein convertase subtilisin kexin type 9 (PCSK9) may play a role in the development of atherosclerosis. Methods We investigated the associations between serum PCSK9 and carotid intima-medial wall thickness (IMT), a measure of subclinical atherosclerosis that predicts cardiovascular events, in 295 asymptomatic subjects from community. Carotid IMT was determined by high-resolution B-mode carotid ultrasonography and serum PCSK9 was measured by immunoassay. Results In univariate analysis, serum PCSK9 concentration was positively (P<0.05 in all) associated with age (r=0.204), BMI (r=0.149), waist circumference (r=0.139), systolic blood pressures (r=0.116), glucose (r=0.211), insulin (r=0.178), HOMA score (r=0.195), plasma triglyceride (r=0.285), total cholesterol (r=0.241) and LDL-cholesterol concentrations (r=0.172). In multivariate regression including male gender, hypertension, smoking status, HOMA score, obesity, LDL-cholesterol, lipoprotein (a) or markers of inflammation, serum PCSK9 remained an independent predictor of mean carotid IMT (P<0.001). Conclusions These data suggest that serum levels of PCSK9 may contribute to increased risk of subclinical carotid atherosclerosis independent of conventional risk factors. Whether PCSK9 inhibition improves cardiovascular outcomes remains to be demonstrated in large, ongoing clinical trials.

    AB - Background Atherosclerosis is a lipid-driven inflammatory disease of the arterial wall involving complex and multifactorial processes. Proprotein convertase subtilisin kexin type 9 (PCSK9) may play a role in the development of atherosclerosis. Methods We investigated the associations between serum PCSK9 and carotid intima-medial wall thickness (IMT), a measure of subclinical atherosclerosis that predicts cardiovascular events, in 295 asymptomatic subjects from community. Carotid IMT was determined by high-resolution B-mode carotid ultrasonography and serum PCSK9 was measured by immunoassay. Results In univariate analysis, serum PCSK9 concentration was positively (P<0.05 in all) associated with age (r=0.204), BMI (r=0.149), waist circumference (r=0.139), systolic blood pressures (r=0.116), glucose (r=0.211), insulin (r=0.178), HOMA score (r=0.195), plasma triglyceride (r=0.285), total cholesterol (r=0.241) and LDL-cholesterol concentrations (r=0.172). In multivariate regression including male gender, hypertension, smoking status, HOMA score, obesity, LDL-cholesterol, lipoprotein (a) or markers of inflammation, serum PCSK9 remained an independent predictor of mean carotid IMT (P<0.001). Conclusions These data suggest that serum levels of PCSK9 may contribute to increased risk of subclinical carotid atherosclerosis independent of conventional risk factors. Whether PCSK9 inhibition improves cardiovascular outcomes remains to be demonstrated in large, ongoing clinical trials.

    U2 - 10.1016/j.hlc.2015.10.017

    DO - 10.1016/j.hlc.2015.10.017

    M3 - Article

    VL - 25

    SP - 520

    EP - 525

    JO - Heart, Lung & Circulation

    JF - Heart, Lung & Circulation

    SN - 1444-2892

    IS - 5

    ER -